8-K: Passage Bio Extends Cash Runway, Gene Therapy Shows Promise

Passage Bio, Inc. reported preliminary unaudited cash of approximately $46 million as of December 31, 2025, extending its cash runway into Q1 2027, alongside positive interim clinical data for its FTD-GRN gene therapy, PBFT02.

Summary

• Preliminary unaudited cash, cash equivalents, and marketable securities were approximately $46 million as of December 31, 2025.
• This cash position is expected to fund operating expenses and capital expenditure requirements into the first quarter of 2027.
• Interim data from the upliFT-D Phase 1/2 trial for PBFT02 in FTD-GRN patients showed robust and durable increases in CSF Progranulin (PGRN).
• PBFT02-treated patients with 12 months follow-up (n=4) had a reduced annual rate of change in plasma NfL (3.7%) compared to published natural history data (29.0% and 28.0%).
• PBFT02 was generally well tolerated, with no serious adverse events related to PBFT02 at Dose 2 and no evidence of thrombotic microangiopathy or dorsal root ganglion (DRG) toxicity.
• The company is pursuing preclinical development of a differentiated gene therapy approach for Huntington's disease, aiming to declare a clinical candidate in 2H 2026.
• Critical manufacturing milestones for PBFT02 have been achieved, including a high-productivity, suspension-based process yielding >1,000 doses per lot and alignment with the FDA on process comparability and functional potency assays.
• Passage Bio plans to initiate discussions with the FDA on a registrational study design for FTD-GRN in 1H 2026, citing unmet need and gene therapy precedents for single-arm registrational approaches.

Sentiment

Score: 8

Explanation: The filing presents strong positive interim clinical data for PBFT02, indicating potential disease modification and a favorable safety profile. The extended cash runway and progress in manufacturing, coupled with plans for FDA discussions on a registrational trial, suggest significant advancement. While the financial data is preliminary and risks inherent to clinical development remain, the overall outlook is highly encouraging for a biotechnology company at this stage.

Positives

• Preliminary cash position of approximately $46 million as of December 31, 2025, provides a cash runway into Q1 2027.
• PBFT02 generated robust, durable increases in CSF Progranulin (PGRN) in FTD-GRN patients, with Dose 1 patients showing levels approaching the upper healthy adult range.
• The first Dose 2 patient (Patient 8) increased CSF PGRN from 1.5 ng/mL at baseline to 7.6 ng/mL at M1, approaching the upper healthy adult range.
• Plasma NfL, a disease progression biomarker, showed early evidence of improvement in PBFT02-treated patients (3.7% annual change) compared to natural history data (29.0% and 28.0%).
• PBFT02 was generally well tolerated, with no serious adverse events related to Dose 2 and no evidence of thrombotic microangiopathy or DRG toxicity.
• Achieved critical manufacturing milestones for PBFT02, including a high-productivity process capable of yielding over 1,000 doses per lot and FDA alignment on comparability and potency assays.
• Planning to initiate discussions with the FDA in 1H 2026 for a registrational study design for FTD-GRN, supported by unmet need and regulatory precedents for single-arm gene therapy trials.
• Preclinical data suggests PBFT02 has potential to correct underlying pathology in FTD-GRN, FTD-C9orf72, and ALS by ameliorating TDP-43 pathology.
• The company's approach for Huntington's disease, decreasing MSH3 expression, is a differentiated strategy.

Negatives

• The reported cash position and financial outlook are preliminary and unaudited, subject to change and final adjustments.
• Serious adverse events related to PBFT02 (venous sinus thrombosis (2), LFT increase (1)) occurred at Dose 1, though they were asymptomatic.
• The comparison of PBFT02 results to other gene therapies is based on public disclosure from different trials, which may be unreliable due to varying designs and patient populations.

Risks

• Ability to develop and obtain regulatory approval for product candidates.
• Timing and results of preclinical studies and clinical trials.
• Risks associated with clinical trials, including managing activities, unexpected concerns from additional data, and obtaining/maintaining regulatory approvals.
• Expectations about healthcare professionals' willingness to use product candidates.
• Timing or amount of adverse safety events.
• Risk that positive results in preclinical or early-stage clinical trials may not be replicated in subsequent or later-stage trials.
• Failure to protect and enforce intellectual property and other proprietary rights.
• Dependence on collaborators and third parties for development and manufacture.
• Timing or amount of receipt of any potential future milestone and royalty payments.
• Risks associated with current and potential delays, work stoppages, or supply chain disruptions.

Future Outlook

Passage Bio expects its current cash position to fund operations into the first quarter of 2027. The company plans to report updated interim safety and biomarker data from Dose 2 in FTD patients and seek regulatory feedback on a registrational trial design for FTD-GRN in the first half of 2026. A clinical candidate for Huntington's disease is expected to be declared in the second half of 2026.

Management Comments

• We are redefining the course of neurodegenerative conditions.
• Advancing clinical stage, potential best-in-class, one-time progranulin raising gene therapy for FTD.
• Pursuing preclinical development of differentiated gene therapy approach in Huntington's disease.
• Cash runway expected into 1Q 2027.

Industry Context

Frontotemporal Dementia (FTD-GRN) is a fatal adult-onset neurodegenerative disease with no approved disease-modifying therapies, representing a substantial unmet clinical need. Huntington's disease is also a fatal, monogenic neurodegenerative disease with no disease-modifying therapy. Passage Bio's gene therapy approach for FTD-GRN, PBFT02, aims to address this by elevating progranulin levels, a strategy that has shown promise in preclinical and early clinical stages. The company's differentiated approach for Huntington's disease by targeting MSH3 expression also positions it within the competitive landscape of gene therapies for neurodegenerative disorders, where several companies are exploring similar modalities.

Comparison to Industry Standards

• PBFT02's AAV1 gene therapy delivering GRN via ICM administration achieved CSF PGRN levels of ~26 ng/mL (mean; n=4) at 12 months, with durability at 18 months (n=2). This compares favorably to other AAV9 gene therapies delivering GRN which showed ~4-8 ng/mL (n=7 higher dose) at 12 months, with declining durability from 2 to 12 months.
• The reduced annual rate of change in plasma NfL (3.7%) for PBFT02-treated patients (n=4) is significantly lower than published natural history data for symptomatic, untreated FTD-GRN patients (29.0% and 28.0%), suggesting a potential disease-modifying effect.
• The company highlights multiple recent gene therapy precedents demonstrating FDA receptivity to a single-arm registrational approach, suggesting alignment with evolving regulatory pathways for rare diseases.

Stakeholder Impact

• Shareholders: Positive impact due to extended cash runway, promising clinical data, and clear path towards regulatory discussions, potentially increasing company valuation.
• Patients (FTD-GRN, Huntington's): Significant positive impact as PBFT02 shows potential as a disease-modifying, one-time therapy for a devastating condition with no approved treatments. Progress in Huntington's also offers future hope.
• Employees: Positive impact from continued progress, stable financial outlook, and advancement of pipeline, potentially fostering job security and morale.
• Regulatory Authorities: Engagement with FDA for registrational study design indicates adherence to regulatory pathways and potential for a novel therapy approval.

Next Steps

• Report updated interim safety and biomarker data from Dose 2 in FTD patients in 1H 2026.
• Seek regulatory feedback on registrational trial design in FTD-GRN in 1H 2026.
• Declare a clinical candidate for Huntington's disease in 2H 2026.
• Continue enrolling patients in Cohort 3 and Cohort 4 of the upliFT-D Phase 1/2 trial.

Key Dates

Recommendation

The filing provides compelling evidence of significant progress for Passage Bio. The preliminary cash runway into Q1 2027 offers financial stability, while the interim Phase 1/2 data for PBFT02 in FTD-GRN is highly encouraging, demonstrating robust and durable increases in a key biomarker (CSF PGRN) and a notable reduction in disease progression biomarker (plasma NfL) compared to natural history. The safety profile appears manageable, especially at Dose 2. Furthermore, the company's achievement of critical manufacturing milestones and its proactive engagement with the FDA for a registrational study design, leveraging precedents for single-arm gene therapy trials, de-risks the development pathway. The preclinical program for Huntington's disease adds further pipeline value. Given the substantial unmet medical need in FTD-GRN and the potential for a best-in-class, one-time gene therapy, these developments suggest a strong upside potential for the stock, warranting a 'strong buy' recommendation for investors with a long-term horizon and appetite for biotechnology risk.

Keywords

Passage Bio, PASG, Gene Therapy, Neurodegenerative, FTD-GRN, Frontotemporal Dementia, Huntington's Disease, PBFT02, Progranulin, Cash Runway, Clinical Trial, SEC Filing, Biotechnology, Orphan Drug, Fast Track, AAV1, Neurofilament Light Chain, NfL, TDP-43, MSH3